A new role for cyclic phosphatidic acid as a PPARgamma antagonist.
A recent study in Molecular Cell (Tsukahara et al., 2010) identifies cyclic phosphatidic acid (CPA) as a naturally occurring PPARgamma antagonist that can be generated from lysophospholipids by signal-dependent activation of phospholipase D2. This endogenous CPA regulates PPARgamma functions required for adipogenesis, glucose homeostasis, and vascular wall biology.